The dominant biomarkers to date are PD-L1 protein expression on tumor cell membranes4 and tumor mutational burden (TMB)8–10, which may underlie the generation of neoantigens that can serve as targets for immune recognition and targeting. Here, CD274 is linked to neoplasm.